Insmed (NASDAQ:INSM) CEO William Lewis Sells 10,699 Shares

Insmed, Inc. (NASDAQ:INSM) CEO William Lewis sold 10,699 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $150.97, for a total transaction of $1,615,228.03. Following the transaction, the chief executive officer directly owned 301,185 shares in the company, valued at $45,469,899.45. This represents a 3.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

William Lewis also recently made the following trade(s):

• On Monday, February 9th, William Lewis sold 13,396 shares of Insmed stock. The shares were sold at an average price of $147.79, for a total value of $1,979,794.84.
• On Tuesday, February 3rd, William Lewis sold 3,009 shares of Insmed stock. The stock was sold at an average price of $156.34, for a total value of $470,427.06.
• On Tuesday, January 20th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $158.93, for a total value of $1,700,392.07.
• On Monday, January 12th, William Lewis sold 19,215 shares of Insmed stock. The stock was sold at an average price of $169.00, for a total value of $3,247,335.00.
• On Thursday, January 8th, William Lewis sold 3,223 shares of Insmed stock. The stock was sold at an average price of $174.17, for a total value of $561,349.91.
• On Wednesday, January 7th, William Lewis sold 2,357 shares of Insmed stock. The shares were sold at an average price of $175.07, for a total value of $412,639.99.
• On Tuesday, January 6th, William Lewis sold 4,096 shares of Insmed stock. The stock was sold at an average price of $173.33, for a total transaction of $709,959.68.
• On Thursday, December 18th, William Lewis sold 10,699 shares of Insmed stock. The stock was sold at an average price of $166.97, for a total transaction of $1,786,412.03.

Insmed Price Performance

Shares of NASDAQ:INSM opened at $159.03 on Tuesday. The firm has a 50 day moving average of $164.37 and a 200-day moving average of $164.24. Insmed, Inc. has a 12 month low of $60.40 and a 12 month high of $212.75. The company has a current ratio of 3.83, a quick ratio of 3.54 and a debt-to-equity ratio of 0.76. The stock has a market capitalization of $34.28 billion, a PE ratio of -24.81 and a beta of 1.11.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.47). Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The firm had revenue of $263.84 million for the quarter, compared to analyst estimates of $263.97 million. During the same quarter in the prior year, the business posted ($1.32) EPS. The business’s revenue was up 152.6% on a year-over-year basis. On average, equities research analysts predict that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Institutional Investors Weigh In On Insmed

Institutional investors have recently added to or reduced their stakes in the business. CIBC Private Wealth Group LLC raised its stake in shares of Insmed by 42.1% during the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 53 shares during the last quarter. Kingsview Wealth Management LLC increased its holdings in Insmed by 2.7% in the third quarter. Kingsview Wealth Management LLC now owns 2,321 shares of the biopharmaceutical company’s stock valued at $334,000 after purchasing an additional 60 shares during the period. Choreo LLC raised its position in Insmed by 2.9% during the 3rd quarter. Choreo LLC now owns 2,319 shares of the biopharmaceutical company’s stock worth $334,000 after purchasing an additional 65 shares during the last quarter. EverSource Wealth Advisors LLC raised its position in Insmed by 10.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 747 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 69 shares during the last quarter. Finally, ORG Partners LLC lifted its holdings in Insmed by 12.7% during the 4th quarter. ORG Partners LLC now owns 657 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 74 shares during the period.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on INSM. Cantor Fitzgerald raised their price objective on Insmed from $216.00 to $230.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. Roth Mkm upgraded shares of Insmed to a “strong-buy” rating in a research note on Friday, January 23rd. Guggenheim decreased their price target on shares of Insmed from $230.00 to $221.00 and set a “buy” rating on the stock in a report on Thursday, December 18th. Rothschild & Co Redburn set a $263.00 price objective on shares of Insmed in a research note on Thursday, December 4th. Finally, UBS Group cut their target price on shares of Insmed from $223.00 to $215.00 and set a “buy” rating on the stock in a research report on Tuesday, January 6th. Three analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $207.86.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.